EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Research Progress on Tamoxifen and Its Analogs Associated With Nuclear Receptors

Ning Dong, Yongli Du iD, Yong Zheng, Haibin Zhang, Huiting Lv, Zhijia Yan

Future Medicinal Chemistry · 2023

DOI: 10.4155/fmc-2023-0092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2023. Verfasst von Ning Dong und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry & Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250353, China. Hauptthemen laut MEDLINE: Tamoxifen, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamoxifen, a triphenylethylene-based selective estrogen-receptor modulator, is a landmark drug for the treatment of breast cancer and is also used for treating liver cancer and osteoporosis. Structural studies of tamoxifen have led to the synthesis of more than 20 novel tamoxifen analogs as receptor modulators, including 16 ERα modulators 2-17, an ERRβ inverse agonist 19 and six ERRγ inverse agonists 20-25. This paper summarizes the research progress and structure-activity relationships of tamoxifen analogs modulating these three nuclear receptors reported in the literature, and introduces the relationship between these three nuclear receptor-mediated diseases and tamoxifen analogs to guide the research of novel tamoxifen analogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenBreast NeoplasmsHumansFemaleDrug Inverse AgonismSelective Estrogen Receptor ModulatorsEstrogen Receptor alphaReceptors, Estrogen

Stichwörter der Autor:innen

ERRβ inverse agonistERRγ inverse agonistsERα modulatorsSARTamoxifen and its analogs

Substanzen

TamoxifenSelective Estrogen Receptor ModulatorsEstrogen Receptor alphaReceptors, Estrogen

Autor:innen und Institutionen

  • School of Chemistry & Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250353, China.

ORCID-Profile: Yongli Du

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Dong, N., Du, Y., Zheng, Y., Zhang, H., Lv, H., & Yan, Z. (2023). Research Progress on Tamoxifen and Its Analogs Associated With Nuclear Receptors. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2023-0092

Vancouver

Dong N, Du Y, Zheng Y, Zhang H, Lv H, Yan Z. Research Progress on Tamoxifen and Its Analogs Associated With Nuclear Receptors. Future Medicinal Chemistry. 2023. doi:10.4155/fmc-2023-0092

BibTeX
@article{Dong2023,
  author = {Dong, Ning and Du, Yongli and Zheng, Yong and Zhang, Haibin and Lv, Huiting and Yan, Zhijia},
  title = {Research Progress on Tamoxifen and Its Analogs Associated With Nuclear Receptors},
  journal = {Future Medicinal Chemistry},
  year = {2023},
  doi = {10.4155/fmc-2023-0092}
}
Kostenlos starten →